Bayer’s 2025 drug sales surge for Nubeqa and Kerendia but dip for Eylea and Xarelto
Bayer AG has reported a mixed bag of results for its pharmaceutical division in the first nine months of 2025. While sales of certain drugs like Nubeqa and Kerendia surged, others such as Eylea and Xarelto faced declines. The company also expects to receive FDA approval for Lynket (elinzanetant) later this month, a non-hormonal treatment for menopausal symptoms.
Bayer's pharmaceutical sales remained steady at around €4.3 billion, similar to the previous year. However, this was largely due to the strong performance of Nubeqa and Kerendia. Nubeqa's sales jumped by 56% for treating prostate cancer, while Kerendia's sales rose by 85% for treating chronic kidney disease linked to type 2 diabetes and heart failure.
Bayer's pharmaceutical division has seen a mixed performance in the first nine months of 2025. While new drugs like Nubeqa and Kerendia have shown promising results, older drugs like Eylea and Xarelto have faced declines. The company's total sales remain robust at around €9.7 billion, but ongoing litigation costs pose a significant challenge. Bayer awaits FDA approval for Lynket, which could provide further growth in the future.
